9 results on '"Kabore, Firmin"'
Search Results
2. Multicountry study of SARS-CoV-2 and associated risk factors among healthcare workers in Côte d'Ivoire, Burkina Faso and South Africa.
- Author
-
Kribi, Sarah, Touré, Fidèle, Mendes, Adriano, Sanou, Soufiane, Some, Arsène, Aminou, Abdoul M, Belarbi, Essia, Griessel, Rosemary, Hema, Arsène, Kabore, Firmin, Pitzinger, Paul, Strydom, Amy, Vietor, Ann Christin, Traoré, Korotimi, Zongo, Arsène, Anoh, Etilé A, Grossegesse, Marica, Hofmann, Natalie, Ouangraoua, Soumeya, and Poda, Armel
- Subjects
SARS-CoV-2 ,MEDICAL personnel - Abstract
Background Reports on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread across Africa have varied, including among healthcare workers (HCWs). This study assessed the comparative SARS-CoV-2 burden and associated risk factors among HCWs in three African countries. Methods A multicentre study was conducted at regional healthcare facilities in Côte d'Ivoire (CIV), Burkina Faso (BF) and South Africa (SA) from February to May 2021. HCWs provided blood samples for SARS-CoV-2 serology and nasopharyngeal/oropharyngeal swabs for testing of acute infection by polymerase chain reaction and completed a questionnaire. Factors associated with seropositivity were assessed with logistic regression. Results Among 719 HCWs, SARS-CoV-2 seroprevalence was 34.6% (95% confidence interval 31.2 to 38.2), ranging from 19.2% in CIV to 45.7% in BF. A total of 20 of 523 (3.8%) were positive for acute SARS-CoV-2 infection. Female HCWs had higher odds of SARS-CoV-2 seropositivity compared with males, and nursing staff, allied health professionals, non-caregiver personnel and administration had higher odds compared with physicians. HCWs also reported infection prevention and control (IPC) gaps, including 38.7% and 29% having access to respirators and IPC training, respectively, in the last year. Conclusions This study was a unique comparative HCW SARS-CoV-2 investigation in Africa. Seroprevalence estimates varied, highlighting distinctive population/facility-level factors affecting COVID-19 burden and the importance of established IPC programmes to protect HCWs and patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. The African Network for Improved Diagnostics, Epidemiology and Management of common infectious Agents.
- Author
-
Schubert, Grit, Achi, Vincent, Ahuka, Steve, Belarbi, Essia, Bourhaima, Ouattara, Eckmanns, Tim, Johnstone, Siobhan, Kabore, Firmin, Kra, Ouffoue, Mendes, Adriano, Ouedraogo, Abdoul-Salam, Poda, Armel, Some, Arsène Satouro, Tomczyk, Sara, Couacy-Hymann, Emmanuel, Kayembe, Jean-Marie, Meda, Nicolas, Muyembe Tamfum, Jean-Jacques, Ouangraoua, Soumeya, and Page, Nicola
- Subjects
EMERGING infectious diseases ,COVID-19 ,HEALTH facilities ,NUCLEOTIDE sequencing ,SARS-CoV-2 ,EPIDEMIOLOGY - Abstract
Background: In sub-Saharan Africa, acute respiratory infections (ARI), acute gastrointestinal infections (GI) and acute febrile disease of unknown cause (AFDUC) have a large disease burden, especially among children, while respective aetiologies often remain unresolved. The need for robust infectious disease surveillance to detect emerging pathogens along with common human pathogens has been highlighted by the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. The African Network for Improved Diagnostics, Epidemiology and Management of Common Infectious Agents (ANDEMIA) is a sentinel surveillance study on the aetiology and clinical characteristics of ARI, GI and AFDUC in sub-Saharan Africa.Methods: ANDEMIA includes 12 urban and rural health care facilities in four African countries (Côte d'Ivoire, Burkina Faso, Democratic Republic of the Congo and Republic of South Africa). It was piloted in 2018 in Côte d'Ivoire and the initial phase will run from 2019 to 2021. Case definitions for ARI, GI and AFDUC were established, as well as syndrome-specific sampling algorithms including the collection of blood, naso- and oropharyngeal swabs and stool. Samples are tested using comprehensive diagnostic protocols, ranging from classic bacteriology and antimicrobial resistance screening to multiplex real-time polymerase chain reaction (PCR) systems and High Throughput Sequencing. In March 2020, PCR testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and analysis of full genomic information was included in the study. Standardised questionnaires collect relevant clinical, demographic, socio-economic and behavioural data for epidemiologic analyses. Controls are enrolled over a 12-month period for a nested case-control study. Data will be assessed descriptively and aetiologies will be evaluated using a latent class analysis among cases. Among cases and controls, an integrated analytic approach using logistic regression and Bayesian estimation will be employed to improve the assessment of aetiology and associated risk factors.Discussion: ANDEMIA aims to expand our understanding of ARI, GI and AFDUC aetiologies in sub-Saharan Africa using a comprehensive laboratory diagnostics strategy. It will foster early detection of emerging threats and continued monitoring of important common pathogens. The network collaboration will be strengthened and site diagnostic capacities will be reinforced to improve quality management and patient care. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso
- Author
-
Penot, Pauline, Hema, Arsene, Bado, Guillaume, Kabore, Firmin, Sore, Ibrahim, Sombie, Diamasso, Traore, Jean-Richard, Guiard-Schmid, Jean-Baptiste, Fontanet, Arnaud, Slama, Laurence, Sawadogo, Adrien Bruno, and Laurent, Christian
- Subjects
Highly active antiretroviral therapy -- Patient outcomes -- Demographic aspects ,Health - Abstract
Introduction: Gender differences in antiretroviral therapy (ART) outcomes are critical in sub-Saharan Africa. We assessed the association between gender and virologic failure among adult patients treated in a public routine clinic (one of the largest in West Africa) in Burkina Faso. Methods: We performed a case-control study between July and October 2012 among patients who had received ART at the Bobo Dioulasso Day Care Unit. Patients were eligible if they were 15 years or older, positive for HIV-1 or HIV-1 + 2, and on first-line ART for at least six months. Cases were all patients with two consecutive HIV loads > 1000 copies/mL (Biocentric Generic or Abbott Real Time assays), or one HIV load >1000 copies/mL associated with immunologic or clinical failure criteria. Controls were all patients who only had HIV loads Results: Of 2303 patients (74.2% women; median age: 40 years; median time on ART: 34 months), 172 had virologic failure and 2131 had virologic success. Among the former, 130 (75.6%) had confirmed virologic failure, 38 (22.1%) had viroimmunologic failure, and four (2.3%) had viro-clinical failure. The proportion of men was significantly higher among the cases than among the controls (37.2% vs. 24.9%; p Conclusions: Men on ART appeared more vulnerable to virologic failure than women. Additional studies are needed to confirm the poorer prognosis of men in this setting and to determine the causes for their vulnerability in order to optimize HIV care. From now on, efforts should be made to support the adherence of men to ART in the African setting. Keywords: HIV; antiretroviral; efficacy; virologic failure; gender; Africa., Introduction Gender differences in antiretroviral therapy (ART) are increasingly recognized as a critical issue in sub-Saharan Africa, where 7.5 million HIV-positive patients are now being treated [1,2]. In this region, [...]
- Published
- 2014
- Full Text
- View/download PDF
5. Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial
- Author
-
Cournil , Amandine, Hema , Arsène, Eymard-Duvernay , Sabrina, Ciaffi , Laura, Badiou , Stéphanie, Kabore , Firmin, Diouf , Assane, Ayangma , Liliane, Le Moing , Vincent, Reynes , Jacques, Koulla-Shiro , Sinata, Delaporte , Eric, Study Group , 2LADY, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Département de biochimie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Recherches Translationnelles sur le VIH et les maladies infectieuses ( TransVIHMI ), Université Montpellier 1 ( UM1 ) -Université Cheikh Anta Diop ( UCAD ) -Universtié Yaoundé 1 (Cameroun)-Université de Montpellier ( UM ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, and Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier )
- Subjects
[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[ SDV.SP.PHARMA ] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology - Abstract
International audience; BACKGROUND:To investigate change in renal function in African patients initiating second-line antiretroviral therapy (ART) including ritonavir-boosted protease inhibitor (PI/r) with or without tenofovir disoproxil fumarate (TDF).METHODS:HIV-1-positive adults, failing standard first-line ART were randomized to either TDF/emtricitabine (FTC)+LPV/r, abacavir + didanosine +LPV/r or TDF/FTC+ darunavir (DRV)/r and followed for 18 months. Patients with an estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m2 at baseline were included in this analysis.RESULTS:Data from 438 out of 454 randomized patients were analysed. Median age was 38 years and 72% were women. Initiation of PI/r-based second-line regimen induced a marked eGFR decline of -10.5 ml/min/1.73 m2 at week 4 in all treatment groups with a greater decrease in TDF/FTC+LPV/r arm (-15.1 ml/min/1.73 m2). At month 18, mean eGFR in the non-TDF containing regimen recovered its baseline level and was significantly greater than eGFR 18-month levels in the TDF-containing regimens that experienced only partial recovery (difference: -10.7; CI -16.8, -4.6; P=0.001 in TDF/FTC+LPV/r and -6.4; CI -12.5, -0.3; P=0.04 in TDF/FTC+DRV/r). At 18 months, prevalence of stage 3 chronic kidney disease was low (60 ml/ml/1.73 m2 at baseline. They also support the recommendation of reassessing renal function 1 month after initiation of treatment including ritonavir to account for the ritonavir-related artefactual decrease of eGFR and determine the new reference baseline value.
- Published
- 2017
6. TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study
- Author
-
Kabore, Firmin Nongodo, primary, Eymard-Duvernay, Sabrina, additional, Zoungrana, Jacques, additional, Badiou, Stéphanie, additional, Bado, Guillaume, additional, Héma, Arsène, additional, Diouf, Assane, additional, Delaporte, Eric, additional, Koulla-Shiro, Sinata, additional, Ciaffi, Laura, additional, and Cournil, Amandine, additional
- Published
- 2017
- Full Text
- View/download PDF
7. Pregnancy rate and birth outcomes among women receiving antiretroviral therapy in Burkina Faso: a retrospective cohort study
- Author
-
Hema, Arsène, primary, Poda, Armel, additional, Konaté, Aina, additional, Kabore, Firmin, additional, Zoungrana, Jacques, additional, Kamboulé, Euloges, additional, Soré, Ibrahim, additional, Bado, Guillaume, additional, Ouédraogo, Abdoul-Salam, additional, Ouédraogo, Macaire, additional, Meda, Nicolas, additional, and Sawadogo, Adrien Bruno, additional
- Published
- 2016
- Full Text
- View/download PDF
8. Evolution of Renal Function in African Patients Initiating Second-Line Antiretroviral Treatment: Findings from the ANRS 12169 2LADY Trial
- Author
-
Cournil, Amandine, Hema, Arsène, Eymard-Duvernay, Sabrina, Ciaffi, Laura, Badiou, Stéphanie, Kabore, Firmin N, Diouf, Assane, Ayangma, Liliane, Le Moing, Vincent, Reynes, Jacques, Koulla-Shiro, Sinata, and Delaporte, Eric
- Abstract
Background To investigate change in renal function in African patients initiating second-line antiretroviral therapy (ART) including ritonavir-boosted protease inhibitor (PI/r) with or without tenofovir disoproxil fumarate (TDF).Methods HIV-1-positive adults, failing standard first-line ART were randomized to either TDF/emtricitabine (FTC)+LPV/r, abacavir + didanosine +LPV/r or TDF/FTC+ darunavir (DRV)/r and followed for 18 months. Patients with an estimated glomerular filtration rate (eGFR) =60 ml/min/1.73 m2at baseline were included in this analysis.Results Data from 438 out of 454 randomized patients were analysed. Median age was 38 years and 72% were women. Initiation of PI/r-based second-line regimen induced a marked eGFR decline of -10.5 ml/min/1.73 m2at week 4 in all treatment groups with a greater decrease in TDF/FTC+LPV/r arm (-15.1 ml/min/1.73 m2). At month 18, mean eGFR in the non-TDF containing regimen recovered its baseline level and was significantly greater than eGFR 18-month levels in the TDF-containing regimens that experienced only partial recovery (difference: -10.7; CI -16.8, -4.6; P=0.001 in TDF/FTC+LPV/r and -6.4; CI -12.5, -0.3; P=0.04 in TDF/FTC+DRV/r). At 18 months, prevalence of stage 3 chronic kidney disease was low (<3%) and not associated with treatment. One treatment discontinuation and five TDF dosage reductions for renal toxicities were reported in TDF-containing arms.Conclusions Overall, these results suggest a reasonable renal tolerance of a regimen associating TDF/FTC+PI/r in African patients with eGFR>60 ml/ml/1.73 m2at baseline. They also support the recommendation of reassessing renal function 1 month after initiation of treatment including ritonavir to account for the ritonavir-related artefactual decrease of eGFR and determine the new reference baseline value.
- Published
- 2017
- Full Text
- View/download PDF
9. Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
- Author
-
Debeaudrap P, Kabore FN, Setha L, Tegbe J, Doukoure B, Sotheara M, Segeral O, Aun K, Messou E, Bitolog P, Sothea K, Vassilakos P, Poda A, Poda EK, Jaquet A, Some A, Petignat P, Clifford G, and Horo A
- Abstract
The WHO recommends the use of human papillomavirus (HPV) testing for primary cervical cancer (CC) screening because of its high sensitivity. However, triage is desirable to correctly identify HPV+ women who have high-grade lesions (CIN2+) and require treatment. The ANRS-12375 study was conducted in Côte d'Ivoire, Burkina Faso and Cambodia to assess the performance, feasibility and benefits of different triage options for detecting CIN2+ lesions: partial (HPV16 and HPV16/18/45) and extended genotyping, visual inspection (VIA) alone and VIA combined with partial genotyping. VIA was performed by gynecologists. The sensitivity, specificity, and diagnostic likelihood ratio (DLR) of each triage option for detecting CIN2+ lesions with histology as a reference standard were calculated. Of the 2253 women living with HIV (WLHIV) included, 932 (41%) were HPV+. A CIN2+ lesion was identified in 105 (13%) of the 777 participants with histopathology results. The sensitivity of VIA as a triage test for CIN2+ patients was 89%, while that for extended genotyping was 89%, that for HPV16/18/45 partial genotyping was 51%, and that for HPV16 partial genotyping was 36%. The specificities for these tests were 45%, 29%, 72%., and 85%, respectively. Combining VIA and/or partial genotyping positivity slightly increased the sensitivity (94%) at the cost of lower specificity (28%). There was significant intersite heterogeneity (p = .04). Among the three triage tests with a sensitivity ≥85%, the VIA had the highest specificity and positive likelihood ratio (p < .001). VIA and extended genotyping, whether independent or combined, are good triage options with high sensitivity for identifying WLHIV needing treatment for CIN2+., (© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.